Want to see BNTC full AI Analyst Report?

Benitec Biopharma (BNTC) Price & Analysis

319 Followers

BNTC Stock Chart & Stats

$13.02

$0.11(0.96%)

At close: Jul 27 4:00 PM EDT

$13.02

$0.11(0.96%)

Day’s Range― - ―

52-Week Range$8.06 - $16.76

Previous CloseN/A

Volume22.11K

Average Volume (3M)177.05K

Market Cap

$282.90M

Enterprise Value$281.17M

Total Cash (Recent Filing)$179.97M

Total Debt (Recent Filing)$762.00K

Price to Earnings (P/E)―

Beta0.99

Next Earnings

Nov 16, 2026

EPS Estimate

-0.27

Next Dividend Ex-DateN/A

Dividend Yield0.12%

Share Statistics

EPS (TTM)-0.98

Shares Outstanding34,882,725

10 Day Avg. Volume212,654

30 Day Avg. Volume177,051

Financial Highlights & Ratios

PEG Ratio2.05

Price to Book (P/B)3.52

Price to Sales (P/S)0.00

P/FCF Ratio-37.48

Enterprise Value/Market Cap0.99

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-584.56

Enterprise Value/Ebitda-5.54

Forecast

1Y Price Target

$24.67

Price Target Upside89.45% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-1.17

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageVery low leverage gives Benitec greater financial flexibility than a heavily indebted biotechnology company. The expanded equity base can help support continued development and reduce balance-sheet pressure while the company works toward clinical milestones and future commercialization.

Regulatory ProgressFormal FDA feedback and an agreed path toward pivotal-trial design confirmation represent meaningful progress for BB-301, the lead program. Maintaining the planned mid-2027 enrollment target could improve development visibility and advance the asset toward a value-defining clinical stage.

Proprietary Gene-silencing PlatformA proprietary ddRNAi platform provides a consistent technological foundation for developing gene-silencing therapies across genetically driven or chronic diseases. Its focus on potentially long-acting treatments may support differentiated product development if clinical results validate durable therapeutic effects.

Bears Say

Pre-revenue BusinessThe absence of meaningful revenue means Benitec currently lacks commercial traction to offset research and development spending. Until a candidate reaches approval and launch, operating performance will remain dependent on clinical progress rather than recurring product revenue.

Widening Net LossesRapidly widening losses indicate that spending is increasing faster than any existing revenue base and that operating leverage has not yet emerged. Persistent negative profitability reduces earnings visibility and leaves the investment case dependent on successful future commercialization of clinical programs.

Persistent Cash BurnSustained negative operating and free cash flow shows that reported losses are translating into real cash outflows. Even with some improvement in 2026, Benitec requires continued funding to sustain operations, creating dependence on external capital until revenues materialize.

Benitec Biopharma News

Benitec Biopharma says BB-301 pivotal still on track for mid-2027

Benitec announced formal FDA feedback following a Type C meeting in Q3. Discussions on an open-label, single-arm pivotal...

15d ago

BNTC

BB-301 Momentum, Favorable FDA Feedback Support Buy Rating with Unchanged $32 Price Target

Benitec Biopharma, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from...

14d ago

BNTC

FDA Clarity on BB-301 Phase 3 Supports Buy Rating on BNTC; $17 Price Target Reiterated

In a report released today, Yun Zhong from Wedbush maintained a Buy rating on Benitec Biopharma, with a...

14d ago

BNTC

Benitec advances BB-301 gene therapy after FDA feedback

Benitec Biopharma ( ($BNTC) ) has shared an update. On October 5, 2026, Benitec Biopharma reported that the...

15d ago

BNTC

BNTC: BB-301 Clinical Progress and Strong Cash Position Drive Ritu Baral’s Buy Rating

TD Cowen analyst Ritu Baral has maintained their bullish stance on BNTC stock, giving a Buy rating yesterday....

1M ago

BNTC

Benitec Biopharma price target raised to $17 from $16 at Wedbush

Wedbush raised the firm’s price target on Benitec Biopharma (BNTC) to $17 from $16 and keeps an Outperform...

1M ago

BNTC

Benitec Biopharma price target raised to $17 from $16 at Wedbush

Wedbush analyst Yun Zhong raised the firm’s price target on Benitec Biopharma (BNTC) to $17 from $16 and...

1M ago

BNTC

Benitec Biopharma files $200M mixed securities shelf

17:11 EDT Benitec Biopharma (BNTC) files $200M mixed securities shelf Published first on TheFly – the ultimate source...

1M ago

BNTC

Wedbush bullish on Benitec Biopharma, initiates with an Outperform

As previously reported, Wedbush initiated coverage of Benitec Biopharma (BNTC) with an Outperform rating and $16 price target...

3M ago

BNTC

Benitec Biopharma initiated with an Outperform at Wedbush

Wedbush initiated coverage of Benitec Biopharma (BNTC) with an Outperform rating and $16 price target Published first on...

3M ago

BNTC

Guggenheim downgrades Benitec to Neutral, terminates coverage

Guggenheim downgraded Benitec Biopharma (BNTC) to Neutral from Buy without a price target while subsequently terminating coverage of...

4M ago

BNTC

Benitec Biopharma downgraded to Neutral from Buy at Guggenheim

Guggenheim analyst Debjit Chattopadhyay downgraded Benitec Biopharma (BNTC) to Neutral from Buy with no price target Published first...

4M ago

BNTC

Benitec Biopharma Announces Board Changes and New Director

Benitec Biopharma ( ($BNTC) ) has provided an update. On May 22, 2026, Benitec Biopharma Inc.’s board appointed...

5M ago

BNTC

Benitec Biopharma: Buy Rating Reiterated on Promising BB-301 Data and Solid Cash Runway; $32 Price Target Maintained

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Benitec Biopharma and keeping the price target...

5M ago

BNTC

BNTC FAQ

What was Benitec Biopharma Ltd’s price range in the past 12 months?

Benitec Biopharma Ltd lowest stock price was $8.06 and its highest was $16.76 in the past 12 months.

What is Benitec Biopharma Ltd’s market cap?

Benitec Biopharma Ltd’s market cap is $282.90M.

When is Benitec Biopharma Ltd’s upcoming earnings report date?

Benitec Biopharma Ltd’s upcoming earnings report date is Nov 16, 2026 which is in 27 days.

How were Benitec Biopharma Ltd’s earnings last quarter?

Benitec Biopharma Ltd released its earnings results on Sep 14, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.264 by $0.004.

Is Benitec Biopharma Ltd overvalued?

According to Wall Street analysts Benitec Biopharma Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Benitec Biopharma Ltd pay dividends?

Benitec Biopharma Ltd pays a Notavailable dividend of $0.765 which represents an annual dividend yield of 0.12%. See more information on Benitec Biopharma Ltd dividends here

What is Benitec Biopharma Ltd’s EPS estimate?

Benitec Biopharma Ltd’s EPS estimate is -0.27.

How many shares outstanding does Benitec Biopharma Ltd have?

Benitec Biopharma Ltd has 34,882,725 shares outstanding.

What happened to Benitec Biopharma Ltd’s price movement after its last earnings report?

Benitec Biopharma Ltd reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.264. Following the earnings report the stock price went down -8.526%.

Which hedge fund is a major shareholder of Benitec Biopharma Ltd?

Currently, no hedge funds are holding shares in BNTC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Benitec Biopharma Stock Smart Score

Underperform

Fundamentals

Return on Equity

-28.41%

Trailing 12-Months

Asset Growth

83.37%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Benitec Biopharma Ltd

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.

Benitec Biopharma (BNTC) Earnings & Revenues

Historic Earnings Reports

BNTC Stock 12 Month Forecast

Average Price Target

$24.67

▲(89.45% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","33":"$33","14.25":"$14.25","20.5":"$20.5","26.75":"$26.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$32.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.666666666666664,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,14.25,20.5,26.75,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.58,11.304615384615385,13.02923076923077,14.753846153846155,16.478461538461538,18.20307692307692,19.927692307692308,21.652307692307694,23.376923076923077,25.10153846153846,26.826153846153844,28.550769230769234,30.275384615384617,{"y":32,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.58,10.740512820512821,11.90102564102564,13.061538461538461,14.222051282051282,15.382564102564102,16.543076923076924,17.703589743589742,18.864102564102563,20.024615384615384,21.1851282051282,22.345641025641022,23.506153846153843,{"y":24.666666666666664,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.58,10.150769230769232,10.721538461538461,11.292307692307693,11.863076923076923,12.433846153846154,13.004615384615384,13.575384615384616,14.146153846153847,14.716923076923077,15.287692307692307,15.858461538461539,16.42923076923077,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.01,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.36,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.23,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.47,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.46,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.83,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.97,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.95,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.82,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.69,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.71,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.31,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.58,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >